LivaNova PLC reported second-quarter 2026 revenue of $390.6 million, a 10.8% increase from the prior year period. The company raised its full-year 2026 adjusted diluted earnings per share guidance to $4.30–$4.40 and constant-currency revenue growth expectations to 8%–9%. A favorable Italian tax ruling resulted in an €81.8 million ($95.4 million) discrete tax benefit related to the SNIA environmental liability. LivaNova also entered a long-term supply agreement with Thermo Fisher Scientific for oxygenator components and announced new executive appointments, including Stefano Folli as President of Cardiopulmonary. The company operates in the medical technology industry, providing solutions for neurological and cardiac conditions.

LivaNova PLC held its 2026 Annual General Meeting of Shareholders on June 10, 2026. Shareholders approved ten proposals, including the election of eleven directors for terms expiring in 2027, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm, and the adoption of the company's audited UK statutory accounts for the year ended December 31, 2025. Additionally, shareholders authorized the directors to allot shares up to an aggregate nominal amount of £10,985,296 and approved terms for share repurchase contracts limited to 10% of the total issued Ordinary Shares. LivaNova PLC is a medical technology company that develops and manufactures products for cardiovascular and respiratory markets.